Dario De Cesare

Dr. Dario De Cesare


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2017 in Stem Cell Reports
Verified
Journal Article
Open access
CDCristina D'ANiello
Cristina D'ANiello
EHEhsan Habibi
Ehsan Habibi
FCFederica Cermola
Federica Cermola
Debora ParisDebora Paris
Debora Paris
FRFrancesco Russo
Francesco Russo
Gabriella MinchiottiGabriella Minchiotti
Gabriella Minchiotti
Metabolites and cofactors are emerging as key regulators of cell plasticity and reprogramming, and their role in the control of pluripotency is just being discovered. Here we provide unprecedented evidence that embryonic stem cell (ESC) pluripotency relies on the relative levels of two physiological metabolites, namely ascorbic acid (vitamin C, VitC) and l-proline (l-Pro), which affect global DNA methylation, transcriptional profile, and energy metabolism. Specifically, while a high VitC/l-Pro ratio drives ESCs toward a naive state, the opposite condition (l-Pro excess) captures a fully reversible early primed pluripotent state, which depends on autocrine fibroblast growth factor and transforming growth factor β signaling pathways. Our findings highlight the pivotal role of metabolites availability in controlling the pluripotency continuum from naive to primed states.

6 July 2022 in Cells
Verified
Journal Article
Open access
PDF file
Gabriella MinchiottiGabriella Minchiotti
Gabriella Minchiotti
CDCristina D'Aniello
Cristina D'Aniello
Annalisa FicoAnnalisa Fico
Annalisa Fico
DCDario De Cesare
Dario De Cesare
EPEduardo Jorge Patriarca
Eduardo Jorge Patriarca
In this paper, we summarize the current knowledge of the role of proline metabolism in the control of the identity of Embryonic Stem Cells (ESCs). An imbalance in proline metabolism shifts mouse ESCs toward a stable naïve-to-primed intermediate state of pluripotency. Proline-induced cells (PiCs), also named primitive ectoderm-like cells (EPLs), are phenotypically metastable, a trait linked to a rapid and reversible relocalization of E-cadherin from the plasma membrane to intracellular membrane compartments. The ESC-to-PiC transition relies on the activation of Erk and Tgfβ/Activin signaling pathways and is associated with extensive remodeling of the transcriptome, metabolome and epigenome. PiCs maintain several properties of naïve pluripotency (teratoma formation, blastocyst colonization and 3D gastruloid development) and acquire a few traits of primed cells (flat-shaped colony morphology, aerobic glycolysis metabolism and competence for primordial germ cell fate). Overall, the molecular and phenotypic features of PiCs resemble those of an early-primed state of pluripotency, providing a robust model to study the role of metabolic perturbations in pluripotency and cell fate decisions.

8 May 2011 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
Laura CasalinoLaura Casalino
Laura Casalino
DMDario Magnani
Dario Magnani
SFSandro De Falco
Sandro De Falco
Stefania FilosaStefania Filosa
Stefania Filosa
GMGabriella Minchiotti
Gabriella Minchiotti
DCDario De Cesare
Dario De Cesare

6 July 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
FAFilomena Amoroso
Filomena Amoroso
EIEduardo Ibello
Eduardo Ibello
FSFederica Saracino
Federica Saracino
FCFederica Cermola
Federica Cermola
GPGiovanna Ponticelli
Giovanna Ponticelli
CDCristina D'Aniello
Cristina D'Aniello
Small molecules that can modulate or stabilize cell–cell interactions are valuable tools for investigating the impact of collective cell behavior on various biological processes such as development/morphogenesis, tissue regeneration and cancer progression. Recently, we showed that budesonide, a glucocorticoid widely used as an anti-asthmatic drug, is a potent regulator of stem cell pluripotency. Here we tested the effect of different budesonide derivatives and identified CHD-030498 as a more effective analogue of budesonide. CHD-030498 was able to prevent stem cell pluripotency exit in different cell-based models, including embryonic stem-to-mesenchymal transition, spontaneous differentiation and 3D gastruloid development, and at lower doses compared to budesonide.

28 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
EPEduardo Jorge Patriarca
Eduardo Jorge Patriarca
CDCristina D'Aniello
Cristina D'Aniello
DCDario De Cesare
Dario De Cesare
GCGilda Cobellis
Gilda Cobellis
Gabriella MinchiottiGabriella Minchiotti
Gabriella Minchiotti
The synthetic cortisol analog budesonide (BUD) is an essential drug employed to manage chronic inflammatory diseases in humans, mainly those involving gastroenteric and airway mucosa, such as rhinitis, laryngitis, bronchitis, esophagitis, gastritis, and colitis, with high levels of success. As a glucocorticoid, BUD prevents the expression of pro-inflammatory cytokines/chemokines and the recruitment of immune cells into the inflamed mucosa. However, emerging evidences indicates that BUD, unlike classical glucocorticoids, is also a potent modulator of stem and cancer cell behavior/plasticity. Certainly, BUD stabilizes cell–cell adhesions preventing embryonic stem cell differentiation and inhibiting the development of 3D gastruloids. In addition, BUD inhibits the motile/invasive propensity of different cancer cells, including breast, lung, and pancreatic cancer. Finally, it prevents the infection with/replication of positive single-stranded human-infecting RNA viruses such as SARS-CoV-2. At a molecular level, BUD induces epigenetic changes and modifies the transcriptome of epithelial, stem and cancer cells, providing molecular support to the immune cell-independent activity of BUD. Here, we performed an in-depth review of these unexpected activities of BUD, identified by unbiased drug screening programs, and emphasize the molecular mechanisms modulated by this efficacious drug that deserve further research.

30 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
FAFilomena Amoroso
Filomena Amoroso
EIEduardo Ibello
Eduardo Ibello
FSFederica Saracino
Federica Saracino
FCFederica Cermola
Federica Cermola
GPGiovanna Ponticelli
Giovanna Ponticelli
CDCristina D'Aniello
Cristina D'Aniello
Small molecules that can modulate or stabilize cell-cell interactions are valuable tools for investigating the impact of collective cell behavior on various biological processes such as development/morphogenesis, tissue regeneration and cancer progression. Recently, we showed that budesonide, a glucocorticoid widely used as anti-asthmatic drug, is a potent regulator of stem cell pluripotency. Here we tested the effect of different budesonide derivatives and identified CHD-030498 as a more effective analogue of budesonide. CHD-030498 was able to prevent stem cell pluripotency exit in different cell-based models, including embryonic stem-to-mesenchymal transition, spontaneous differentiation and 3D gastruloid development, and at lower doses compared to budesonide.